Exenatide

Short-acting exenatide “does not seem to have a future” as a standard adjunct treatment in people with type 1 diabetes, say the MAG1C investigators.

Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.

A meta-analysis published in The Lancet Diabetes & Endocrinology is suggestive of a class cardioprotective effect for the glucagon-like peptide-1 receptor agonists.

The results of the Exenatide Study of Cardiovascular Event Lowering study show that the glucagon-like peptide-1 receptor agonist has a neutral cardiovascular effect, the investigators have reported at the EASD annual meeting, in Lisbon, Portugal.

One of the first original research sessions of EASD 2017 included updates from the TECOS, SUSTAIN 6, and DURATION-7 and -8 trials.

The 52-week findings of the DURATION-8 trial show durable glycemic control with the combination of exenatide and dapagliflozin in patients with type 2 diabetes.

One of the final sessions on Saturday featured the presentation of new, and mostly positive, data on medications for glycemic control in patients with type 2 diabetes.

Combining a glucagon-like peptide-1 receptor agonist with a sodium-glucose co-transporter-2 inhibitor improves glycaemic control more than either therapy alone in patients with Type 2 diabetes, shows the DURATION-8 trial.